Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 18Carcinoma, Hepatocellular 9Neoplasms 8Melanoma 7Squamous Cell Carcinoma of Head and Neck 6Nasopharyngeal Carcinoma 6Triple Negative Breast Neoplasms 5Esophageal Neoplasms 5Neoplasm Metastasis 4Esophageal Squamous Cell Carcinoma 4Colonic Neoplasms 4Recurrence 3Rectal Neoplasms 3Pancreatic Neoplasms 3Lung Neoplasms 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Stomach Neoplasms 2Solid Cancers 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Ovarian Neoplasms 2Gastric / Gastroesophageal Junction Adenocarcinoma 2EBV-associated Tumors 2Cholangiocarcinoma 2Breast Neoplasms 2Bites and Stings 2Biliary Tract Neoplasms 2Advanced Solid Tumors 2

Interventions

Pemetrexed 1Immune Checkpoint Inhibitors 1Drug Therapy 1Carboplatin 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
First-line Advanced NSCLC Patients × Immune Checkpoint Inhibitors × 1 year × Clear all
NCT07171606 2025-12-18

A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer(NSCLC) Patients

Shenyang Sunshine Pharmaceutical Co., LTD.

Phase 2 Recruiting
240 enrolled
Thoracic

First-line Advanced NSCLC Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡